OLEMA PHARMACEUTICALS INC (OLMA) Fundamental Analysis & Valuation

NASDAQ:OLMA • US68062P1066

Current stock price

15.53 USD
+0.18 (+1.17%)
At close:
15.53 USD
0 (0%)
After Hours:

This OLMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OLMA Profitability Analysis

1.1 Basic Checks

  • OLMA had negative earnings in the past year.
  • In the past year OLMA has reported a negative cash flow from operations.
  • In the past 5 years OLMA always reported negative net income.
  • In the past 5 years OLMA always reported negative operating cash flow.
OLMA Yearly Net Income VS EBIT VS OCF VS FCFOLMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.45%, OLMA is in the better half of the industry, outperforming 65.12% of the companies in the same industry.
  • OLMA has a better Return On Equity (-33.95%) than 72.09% of its industry peers.
Industry RankSector Rank
ROA -30.45%
ROE -33.95%
ROIC N/A
ROA(3y)-31.35%
ROA(5y)-33.34%
ROE(3y)-34.56%
ROE(5y)-36.34%
ROIC(3y)N/A
ROIC(5y)N/A
OLMA Yearly ROA, ROE, ROICOLMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OLMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OLMA Yearly Profit, Operating, Gross MarginsOLMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

5

2. OLMA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for OLMA has been increased compared to 1 year ago.
  • OLMA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for OLMA is higher compared to a year ago.
OLMA Yearly Shares OutstandingOLMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
OLMA Yearly Total Debt VS Total AssetsOLMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • OLMA has an Altman-Z score of 13.00. This indicates that OLMA is financially healthy and has little risk of bankruptcy at the moment.
  • OLMA's Altman-Z score of 13.00 is amongst the best of the industry. OLMA outperforms 84.11% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that OLMA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, OLMA is in line with its industry, outperforming 47.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 13
ROIC/WACCN/A
WACCN/A
OLMA Yearly LT Debt VS Equity VS FCFOLMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • OLMA has a Current Ratio of 9.95. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
  • OLMA's Current ratio of 9.95 is fine compared to the rest of the industry. OLMA outperforms 78.88% of its industry peers.
  • A Quick Ratio of 9.95 indicates that OLMA has no problem at all paying its short term obligations.
  • The Quick ratio of OLMA (9.95) is better than 79.07% of its industry peers.
Industry RankSector Rank
Current Ratio 9.95
Quick Ratio 9.95
OLMA Yearly Current Assets VS Current LiabilitesOLMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

1

3. OLMA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.84% over the past year.
EPS 1Y (TTM)15.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • OLMA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.98% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-23.6%
EPS Next 2Y-17%
EPS Next 3Y-3%
EPS Next 5Y2.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OLMA Yearly Revenue VS EstimatesOLMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
OLMA Yearly EPS VS EstimatesOLMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2 -2.5

0

4. OLMA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OLMA. In the last year negative earnings were reported.
  • Also next year OLMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OLMA Price Earnings VS Forward Price EarningsOLMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OLMA Per share dataOLMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as OLMA's earnings are expected to decrease with -3.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17%
EPS Next 3Y-3%

0

5. OLMA Dividend Analysis

5.1 Amount

  • OLMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OLMA Fundamentals: All Metrics, Ratios and Statistics

OLEMA PHARMACEUTICALS INC

NASDAQ:OLMA (4/24/2026, 8:00:39 PM)

After market: 15.53 0 (0%)

15.53

+0.18 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-12
Inst Owners100.87%
Inst Owner Change-0.03%
Ins Owners2.56%
Ins Owner Change-11.29%
Market Cap1.35B
Revenue(TTM)N/A
Net Income(TTM)-162.45M
Analysts85.26
Price Target42.33 (172.57%)
Short Float %14.47%
Short Ratio6.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.98%
Min EPS beat(2)0.67%
Max EPS beat(2)7.28%
EPS beat(4)3
Avg EPS beat(4)1.44%
Min EPS beat(4)-32.98%
Max EPS beat(4)30.8%
EPS beat(8)5
Avg EPS beat(8)3.72%
EPS beat(12)8
Avg EPS beat(12)5.69%
EPS beat(16)11
Avg EPS beat(16)4.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.42%
PT rev (3m)-7.78%
EPS NQ rev (1m)-1.94%
EPS NQ rev (3m)2.97%
EPS NY rev (1m)0.27%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 2.83
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)-2.3
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS5.49
TBVpS5.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.45%
ROE -33.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.35%
ROA(5y)-33.34%
ROE(3y)-34.56%
ROE(5y)-36.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.95
Quick Ratio 9.95
Altman-Z 13
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-23.6%
EPS Next 2Y-17%
EPS Next 3Y-3%
EPS Next 5Y2.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.79%
EBIT Next 3Y1.56%
EBIT Next 5Y24.13%
FCF growth 1Y-40.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.6%
OCF growth 3YN/A
OCF growth 5YN/A

OLEMA PHARMACEUTICALS INC / OLMA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OLEMA PHARMACEUTICALS INC (OLMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OLMA.


What is the valuation status of OLEMA PHARMACEUTICALS INC (OLMA) stock?

ChartMill assigns a valuation rating of 0 / 10 to OLEMA PHARMACEUTICALS INC (OLMA). This can be considered as Overvalued.


Can you provide the profitability details for OLEMA PHARMACEUTICALS INC?

OLEMA PHARMACEUTICALS INC (OLMA) has a profitability rating of 1 / 10.


What is the financial health of OLEMA PHARMACEUTICALS INC (OLMA) stock?

The financial health rating of OLEMA PHARMACEUTICALS INC (OLMA) is 5 / 10.